🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. DEFLAN 22,75 mg/ml gocce orali, sospensione

    Sana Biotechnology

    Laminopathies

    phase 2 small molecule active

    1 trial

  2. DEXAMETHASONE SODIUM PHOSPHATE, VELCADE 3.5 mg powder for solution for injection, DARATUMUMAB, CYCLOPHOSPHAMIDE

    Janssen-Cilag International N.V.

    Amyloid Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  3. DEXAMETHASONE, CYCLOPHOSPHAMIDE, VINCRISTINE SULFATE, METHOTREXATE, LEVETIRACETAM, Blinatumomab SC2, Blinatumomab SC1, CYTARABINE

    Amgen

    Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,

    phase 2 small molecule active

    1 trial

  4. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  5. DNA vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AIDS

    phase 2 mab completed

    1 trial

  6. DOCETAXEL , PACLITAXEL , GEMCITABINE , VINORELBINE , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , Inflectra 100 mg powder for concentrate for solution for infusion, Micofenolato de mofetil Generis 250 mg Cápsulas

    AstraZeneca AB

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  7. DONEPEZIL ARROW 5 mg, comprimé pelliculé, The placebo has the same container composition as the investigational medicinal product (exception of the active substance) and is manufactured by the same manufacturer (pui of the brest university hospital) according to the same procedures as the investigational medicinal product. the active substance is lactose monohydrate, ARICEPT 5 mg, comprimé pelliculé, DONEPEZIL BIOGARAN 5 mg, comprimé pelliculé

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  8. DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  9. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  10. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  11. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  12. DRUID AI Program

    Hospital Authority, Hong Kong

    Solid Organ Malignancies

    phase 2 other active

    1 trial

  13. DS-8201a

    Ningbo Cancer Hospital

    Metastatic Breast Cancer HR+, HER2-

    phase 2 small molecule active

    1 trial

  14. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  15. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Danggui Buxue Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  17. Daratumumab Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  18. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  19. Darovasertib

    Hospital Authority, Hong Kong

    Ocular Melanoma

    phase 2 small molecule completed

    1 trial

  20. Dasatinib/Teva 50 mg επικαλυμμένα με λεπτό υμένιο δισκία, Maltodextrine powder, SPRYCEL 20 mg film-coated tablets

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

  21. Daunorubicin

    Hospital Authority, Hong Kong

    Down Syndrome

    phase 2 small molecule active

    1 trial

  22. Decitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 2 small molecule terminated

    1 trial

  23. Decitabine

    Shanghai Tong Ren Hospital

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  24. Deep-sea fish oil

    The First People's Hospital of Lianyungang

    Radiation Toxicity

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources